E. N. Griep

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol

M.K. Reinders, Eric N. van Roon, Tim Jansen et al. · Annals of the Rheumatic Diseases · 2008 · 159 citations

Cognitive and personality function in myotonic muscular dystrophy.

Thomas D. Bird, Christine Follett, E. N. Griep · Journal of Neurology Neurosurgery & Psychiatry · 1983 · 91 citations · Full text

Neuropsychology, Physical Handicap, Corticobasal Degeneration +17

Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab — The GO-EASY Study

Rianne E. van Bentum, Sjoerd C. Heslinga, Michael T. Nurmohamed et al. · The Journal of Rheumatology · 2018 · 69 citations · Full text

Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial

Laurette van Boheemen, Samina A. Turk, Marian H. van Beers-Tas et al. · RMD Open · 2021 · 69 citations · Full text